company background image
A228760

Genomictree KOSDAQ:A228760 Stock Report

Last Price

₩9.13k

Market Cap

₩188.5b

7D

-4.4%

1Y

-25.2%

Updated

27 Nov, 2022

Data

Company Financials
A228760 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

A228760 Stock Overview

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases.

Genomictree Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Genomictree
Historical stock prices
Current Share Price₩9,130.00
52 Week High₩14,600.00
52 Week Low₩8,310.00
Beta0.72
1 Month Change0.33%
3 Month Change-17.38%
1 Year Change-25.16%
3 Year Change-57.63%
5 Year Change20.93%
Change since IPO102.89%

Recent News & Updates

Recent updates

What You Need To Know About Genomictree Inc.'s (KOSDAQ:228760) Investor Composition

Feb 11
What You Need To Know About Genomictree Inc.'s (KOSDAQ:228760) Investor Composition

Shareholder Returns

A228760KR BiotechsKR Market
7D-4.4%-3.2%-0.3%
1Y-25.2%-40.8%-19.7%

Return vs Industry: A228760 exceeded the KR Biotechs industry which returned -40.8% over the past year.

Return vs Market: A228760 underperformed the KR Market which returned -19.7% over the past year.

Price Volatility

Is A228760's price volatile compared to industry and market?
A228760 volatility
A228760 Average Weekly Movement4.6%
Biotechs Industry Average Movement8.1%
Market Average Movement6.6%
10% most volatile stocks in KR Market11.6%
10% least volatile stocks in KR Market3.9%

Stable Share Price: A228760 is less volatile than 75% of KR stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: A228760's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200082Sung-Whan Anhttps://www.genomictree.com

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraTect-KRAS and AccuraTect-BRAF that are companion diagnostics for colorectal cancer; AccuraTect-EGFR, a companion diagnostic for lung cancer; and AccuraDTect SARS-CoV-2 RT-qPCR kits, as well as test providers.

Genomictree Inc. Fundamentals Summary

How do Genomictree's earnings and revenue compare to its market cap?
A228760 fundamental statistics
Market Cap₩188.50b
Earnings (TTM)-₩4.52b
Revenue (TTM)₩30.83b

6.1x

P/S Ratio

-41.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A228760 income statement (TTM)
Revenue₩30.83b
Cost of Revenue₩5.02b
Gross Profit₩25.81b
Other Expenses₩30.32b
Earnings-₩4.52b

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-218.83
Gross Margin83.71%
Net Profit Margin-14.65%
Debt/Equity Ratio23.5%

How did A228760 perform over the long term?

See historical performance and comparison